Literature DB >> 4331799

Concentrations of idoxuridine in serum, urine, and cerebrospinal fluid of patients with suspected diagnoses of Herpesvirus hominis encephalitis.

A M Lerner, E J Bailey.   

Abstract

A reproducible microbiologic assay of microgram quantities of idoxuridine (IDU) in serum, urine, or cerebrospinal fluid is presented. The antiviral assay is not interfered with by type-specific antibody or interferon. During slow intravenous infusions of idox-uridine (4 mg/min) in patients with suspected diagnoses of Herpesvirus hominis encephalitis, the rate of inactivation and/or removal of drug exceeded its administration. During several rapid infusions of idoxuridine (50 mg/min) significant quantities of the drug were found in serum, urine, and cerebrospinal fluid. Idoxuridine is not significantly bound to serum proteins and is not deiodinated in fresh serum or urine in vitro to inactive products (iodouracil, uracil, iodide). It is rapidly excreted into the urine. Inactivation of IDU occurs in tissues. This antiviral assay of IDU in body fluids should be applicable to other viruses and potential antiviral agents. Minimal inhibitory concentrations of IDU for fresh isolates of Herpesvirus hominis (type 1 or 2) were determined. Type 1 herpesviruses' microplaques in baby hamster kidney cell (BHK 21) tissue cultures were sensitive to 2.5-10 mug/0.4 ml. Type 2 macroplaques required 25-50 mug/0.4 ml. This latter characteristic may be an additional biologic marker which may be useful in suggesting type-specificity of herpesvirus isolates.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4331799      PMCID: PMC332927          DOI: 10.1172/JCI106795

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

Review 1.  INTERFERON.

Authors:  A ISAACS
Journal:  Adv Virus Res       Date:  1963       Impact factor: 9.937

2.  A biologic comparison of two strains of Herpesvirus hominis.

Authors:  T F SCOTT; D L McLEOD; T TOKUMARU
Journal:  J Immunol       Date:  1961-01       Impact factor: 5.422

3.  The isolation and properties of a variant of Herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody.

Authors:  M D HOGGAN; B ROIZMAN
Journal:  Am J Hyg       Date:  1959-09

4.  The fate of 5-iodo-2'-deoxyuridine (IUdR) in plasma and cerebrospinal fluid of dogs.

Authors:  D R Clarkson; W W Oppelt; P Byvoet
Journal:  J Pharmacol Exp Ther       Date:  1967-09       Impact factor: 4.030

5.  Plaque assay of Herpesvirus hominis on human embryonic fibroblasts.

Authors:  B B Wentworth; L French
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

6.  Antibodies to Herpesvirus hominis types 1 and 2 in the rabbit.

Authors:  A J Nahmias; W R Dowdle; J H Kramer; C F Luce; S C Mansour
Journal:  J Immunol       Date:  1969-04       Impact factor: 5.422

7.  Herpes simplex infection of the female genital tract. II. Association of cytopathic effect in cell culture with site of infection.

Authors:  B Kleger; J E Prier
Journal:  J Infect Dis       Date:  1969-09       Impact factor: 5.226

8.  Plaque titration of herpes simplex with antibody-free liquid overlay.

Authors:  C E Wheeler; R A Briggaman; R R Henderson
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

9.  Association of antigenic type of Herpesvirus hominis with site of viral recovery.

Authors:  W R Dowdle; A J Nahmias; R W Harwell; F P Pauls
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

10.  Density difference of DNA of human herpes simplex viruses, types I and II.

Authors:  C R Goodheart; G Plummer; J L Waner
Journal:  Virology       Date:  1968-07       Impact factor: 3.616

View more
  5 in total

1.  Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination.

Authors:  K J Champney; C B Lauter; E J Bailey; A M Lerner
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

2.  [Herpes simplex encephalitis in newborns. Treatment with 5-iodo-2'-deoxyuridin? (author's transl)].

Authors:  R Nüssli; H P Kind; G Duc
Journal:  Eur J Pediatr       Date:  1976-05-04       Impact factor: 3.183

3.  Assessment of cytosine arabinoside as an antiviral agent in humans.

Authors:  C B Lauter; E J Bailey; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

4.  Factors indicative of outcome in a comparative trial of acyclovir and vidarabine for biopsy-proven herpes simplex encephalitis.

Authors:  R J Whitley; C A Alford; M S Hirsch; R T Schooley; J P Luby; F Y Aoki; D Hanley; A J Nahmias; S J Soong
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 5.  Antiviral therapy.

Authors:  H Stalder
Journal:  Yale J Biol Med       Date:  1977 Sep-Oct
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.